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Antifungal activity of Lactobacillus against
Microsporum canis, Microsporum gypseum
and Epidermophyton floccosum
Jiahui Guo,1 Brid Brosnan,2 Ambrose Furey,2 Elke K. Arendt,3 Padraigin Murphy1 and Aidan Coffey1,*
1Department of Biological Sciences; Cork Institute of Technology; Cork, Ireland; 2Team Elucidate; Department of Chemistry; Cork Institute of Technology; Cork, Ireland;
3Department of Food Science; Food Technology and Nutrition; National University of Ireland; Cork, Ireland
Keywords: antifungal, lactic acid bacteria, Microsporum canis, Microsporum gypseum, Epidermophyton floccosum
Abbreviations: WHO, World Health Organization; LAB, lactic acid bacteria; LC-FTMS, liquid chromatography fourier transform mass
Spectrometry; PDA, potato dextrose agar; SDA, sabouraud dextrose agar; SNB, synthetic-nutrient-poor bouillon; mMRS, modified MRS
agar; cfs, freeze-dried cell free supernatant; cfsP, antifungal strain Lb. reuteri ee1p freeze-dried cell-free supernatant; cfsN, negative control
strain Lb. reuteri M13 freeze-dried cell-free supernatant; cfsC, freeze-dried mMRS broth; SDB, Sabouraud dextrose broth
A total of 220 lactic acid bacteria isolates were screened for antifungal activity using Aspergillus fumigatus and Aspergillus
niger as the target strains. Four Lactobacillus strains exhibited strong inhibitory activity on agar surfaces. All four were also
identified as having strong inhibitory activity against the human pathogenic fungi Microsporum canis, Microsporum gypseum
and Epidermophyton floccosum. One of the four lactobacilli, namely Lb. reuteri ee1p exhibited the most inhibition against
dermatophytes. Cell-free culture supernatants of Lb. reuteri ee1p and of the non-antifungal Lb. reuteriM13 were freeze-dried
and used to access and compare antifungal activity in agar plate assays and microtiter plate assays. Addition of the Lb. reuteri
ee1p freeze-dried cell-free supernatant powder into the agar medium at concentrations greater than 2% inhibited all fungal
colony growth. Addition of the powder at 5% to liquid cultures caused complete inhibition of fungal growth on the basis of
turbidity. Freeze-dried supernatant of the non-antifungal Lb. reuteriM13 at the same concentrations had amuch lesser effect.
As Lb. reuteri M13 is very similar to the antifungal strain ee1p in terms of growth rate and final pH in liquid culture, and as it
has little antifungal activity, it is clear that other antifungal compounds must be specifically produced (or produced at higher
levels) by the anti-dermatophyte strain Lb. reuteri ee1p. Reuterin was undetectable in all four antifungal strains. The cell free
supernatant of Lb. reuteri ee1p was analyzed by LC-FTMS using an Accela LC coupled to an LTQ Orbitrap XL mass
spectrometer. The high mass accuracy spectrum produced by compounds in the Lb. reuteri ee1p strain was compared with
both a multianalyte chromatogram and individual spectra of standard anti-fungal compounds, which are known to be
produced by lactic acid bacteria. Ten antifungal metabolites were detected.
Introduction
Cutaneous mycoses are among the most common fungal infec-
tions and are mostly caused by filamentous keratinophilic fungi
that use keratin as a nutrient during skin, scalp and nail infec-
tions. Pathogens responsible for skin mycoses are primarily anthro-
pophilic and zoophilic dermatophytes and include the genera
Microsporum and Epidermophyton. These fungi attack various
parts of the body and the resulting diseases are often called
ringworm or tinea. According to the World Health Organization
(WHO), dermatophytes affect about 25% of the world popula-
tion. It is estimated that from 30 to 70% of adults are asym-
ptomatic hosts of these pathogens and that the incidence of the
disease increases with age.1,2 Although many antifungal agents
have been developed in recent decades and have become avail-
able for the treatment of dermatophytosis, they are confined to
relatively few chemical groups. In addition, the occurrence of
resistance or side effects in clinically isolated strains leads to
failure in the treatment of mycoses.3-7 Apart from side-effects
like liver-damage or affecting estrogen levels, many medicines
can cause allergic reactions. For example, the azole group of
drugs is known to cause anaphylaxis.8 There are also many drug
interactions, the azole antifungals such as ketoconazole or
itraconazole can be both substrates and inhibitors of the P-
glycoprotein, which (among other functions) excretes toxins and
drugs into the intestines.9 Azole antifungals also are substrates
and inhibitors of the cytochrome P450 family CYP3A4, causing
increased concentration when administering, for example, with
calcium channel blockers, immunosuppressants, chemotherapeu-
tic drugs, benzodiazepines, tricyclic antidepressants, macrolides
and SSRIs.10-12 The polyene antimycotics are crucial agents in
the management of serious systemic fungal infections. Despite
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this, their known side effects and toxicity will sometimes require
discontinuation of therapy despite a life-threatening systemic
fungal infection.13 Polyene antimycotics administration is limited
by infusion-related toxicity, an effect postulated to result from
proinflammatory cytokine production. The principal acute toxi-
city of Amphotericin B deoxycholate includes nausea, vomiting,
rigors, fever, hypertension or hypotension, and hypoxia. Its
principal chronic adverse effect is nephrotoxicity.14,15 Essentially,
the majority of the clinically-used antifungals suffer from various
drawbacks in terms of toxicity, drug-drug interactions, and lack
of fungicidal efficacy, cost and emergence of resistant strains.
In spite of the recent introduction of new antifungal drugs, they
are still limited in number. Hence, there is a great demand for
novel antifungal agents, justifying the intense search for new
drugs that are more effective and less toxic than those already in
use.16-19
Lactic acid bacteria (LAB) are widely used in food and feed
fermentation, contributing to the safety, stability, flavor and struc-
ture of food/feed products. Antimicrobial compounds produce
by LAB include: organic acids, hydrogen peroxide, diacetyl, CO2
and bacteriocins. There is extensive knowledge about the anti-
bacterial effects by bacteriocins20-23 whereas the number of pub-
lished studies on the identification of antifungal agents from LAB
is rather limited and to date, these are focused on food-associated
fungi such as Fusarium, Aspergillus and Penicillium.24-27
Antifungal compounds from LAB involve metabolites derived
from organic acids, proteinaceous compounds and other low
molecular mass compounds (less than 1,000 Da). Several of these
compounds have been isolated and shown to have the ability to
retard or eliminate fungal growth or spore outgrowth, either on
their own or synergistically.28-32
Given their food grade status, the collections of lactic acid
bacteria were screened as a possible source of antifungal activity
against dermatophytes. Two relatively safe, fast-growing fungi
were used as targets with the aim of finding strains, which might
be inhibitory to the infectious fungi Microsporum canis, Micro-
sporum gypseum and Epidermophyton floccosum. The antifungal
activity of LAB was demonstrated in bioassays with fungi
cultivated in defined medium on agar plates or in liquid cultures.
Results
Screening for antifungal activity of LAB. The sources of LAB
isolates included pigs, human infants, mice, cows, sourdough,
cheese and cereal samples. Two hundred twenty strains were
isolated in total. Their screening for antifungal activity was
investigated by streaking out the bacteria in two parallel lines
onto mMRS plates inoculated with A. fumigatus and A. niger
spores and mycelia. The antifungal activity was evaluated at 30°C
as well as 37°C. Incubation at 37°C resulted in a higher number
of LAB showing anti-fungal activity against these species. At this
temperature, around 40% of the isolates inhibited A. fumigatus,
compared with 29% at 30°C; around 60% of the isolates
inhibited A. niger, compared with 39% at 30°C. Overall, 77% of
the isolates inhibited one fungus, 43% of all isolates showed
some degree of antifungal activity against both target fungi.
Interestingly, only 12 strains exhibited antifungal activity against
two Aspergillus at both temperatures. More LAB isolates from
the bovine (83%), human (74%) and porcine (68%) groups
showed antifungal activity than isolates from the other sources.
Nevertheless, in the majority of cases, the antifungal activity was
considered to be weak.
The four strongest antifungal LAB (i.e., showing strong
inhibition against both Aspergillus species) were identified and
their inhibition profile at both incubation temperatures is
summarized in Table 1. Four negative control strains (of the
same species) are included. All eight strains were then screened
against M. canis DSM10708, M. gypseum DSM3824 and
E. floccosum DSM10709. Sizes of clear zones of antifungal
activity against the fungi were recorded and these are shown in
Table 2. All four antifungal LAB strains also inhibited the three
dermatophytes. One, namely Lb. reuteri ee1p, was selected for
Table 1. Summary of antifungal activity of isolated lactic acid bacteria
against selected Aspergillus species (incubation was performed at 37°C or
30°C)
Strain A. niger A.fumigatus Strain origin
37°C 30°C 37°C 30°C
Lactobacillus arizonensis (R13) + + + + cheese
Lactobacillus arizonensis (R14) - - - - human
Lactobacillus brevis (JJ2p) + - + ++ porcine
Lactobacillus brevis (NL) - - - - sourdough
Lactobacillus casei (R4) ++ +++ + + human
Lactobacillus casei (R21) - - - - human
Lactobacillus reuteri (ee1p) + ++ +++ - porcine
Lactobacillus reuteri (M13) - - - - murine
The distance between the peripheral sides of the bacterial-lines and the
starting growth zone was scored as follows: -, no clear zone; +, distance
$ 3 mm; ++, distance $ 5 mm; +++, distance $ 8 mm.
Table 2. Zone sizes (mm) around bacterial streaks indicating antifungal
activity of lactic acid bacteria against the dermatophytes Microsporum canis,
Microsporum gypseum and Epidermophyton floccosum. The table includes
the most inhibitory antifungal LAB strain and a negative control strain for
each, indicated by an asterisk. Negative control strains have the same
growth rates and exhibit the same final culture pH as their respective
antifungal partner
















Lactobacillus casei R4 4 10 10
Lactobacillus casei R21* 0 4 5
Lactobacillus reuteri ee1p 5 20 35
Lactobacillus reuteri M13* 0 2 2
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further study. It was observed to have very strong anti-
dermatophyte activity at 30°C in that the distances between the
peripheral sides of the bacterial-lines and the starting fungal
growth zone were generally large (Table 2). The negative control
strain Lb. reuteri M13 does appear to cause a weakened fungal
growth adjacent to the LAB streak in some cases. However, on
close observation, the fungal mycelium did come in co tact with
the LAB colonies in these cases. This did not occur with
Lb. reuteri ee1p, where there is definite inhibition of M. canis,
M. gypseum and E. floccosum mycelial growth typified by large
zones (Table 2; Figs. 1 and 2). Lb. reuteri M13 was the most
appropriate negative control strain as its growth rate and acid-
producing ability in liquid medium were almost identical to that
of Lb. reuteri ee1p (Fig. 3).
To account for the influence of acidic conditions on fungal
mycelia’s growth, M. canis, M. gypseum and E. floccosum were
independently grown for 15 d on SD agar surface at pHs ranging
from 2.0 to 9.0. Colony diameters were shown to be same at pHs
3.5 to 8.0 for all the selected fungi. At pH 3.0, the growth of all
fungi was reduced, while at pH 2.5 or less, no fungal growth
occurred. The data are summarized in Table 3. It indicated that
while low pH did have a slight effect on fungal inhibition, other
factor(s) related to Lb. reuteri ee1p was contributing to the
inhibition. In addition, the acid-producing ability during growth
of the four antifungal LABs and the four negative control
strains (of the same species) were also assessed (Fig. 3). The acid
producing ability of both bacterial strains in each pair of positive
and negative LAB is similar.
Analysis for presence of reuterin by colorimetric assay.
3-hydroxypropionaldehyde (3-HPA), also known as reuterin,
is an antimicrobial compound produced by Lb. reuteri. The
presence or absence of reuterin was evaluated using a colorimetric
assay. Acrolein at 0.05 mM 0.5 mM, and 50 mM were used as the
positive controls (3-HPA is a precursor to acrolein, 1 mol of
3-HPA dehydrates to 1 mol of acrolein). Optical densities of
acrolein solutions at 605 nm were observed to be 0.090
(0.05 mM), 0.451 (0.5 mM) and 0.870 (50 mM). Lb. reuteri
ee1p did not yield any colorimetric change, indicating a lack of
production of reuterin at levels greater than 0.05 mM.
Identification of antifungal compounds in Lb. reuteri ee1p
using LC-FTMS. The cell free supernatant of Lb. reuteri ee1p
was analyzed by liquid chromatography Fourier transform
mass spectrometry (LC-FT-MS) using an Accela LC instrument
coupled to a LTQ Orbitrap XL mass spectrometer. The high mass
accuracy spectrum produced by compounds in the Lb. reuteri
ee1p strain was compared with both a multianalyte chromatogram
Figure 1. Antifungal activity of Lb. reuteri ee1p against M. gypseum. (A) M. gypseum grown 15 d at 30°C on mMRS agar plate with no LAB present.
(B) M. gypseum grown with negative control Lb. reuteri M13. (C) M. gypseum grown with Lb. reuteri ee1p showing clear zones of fungal inhibition.
Figure 2. Antifungal activity of Lb. reuteri ee1p against Epidermophyton floccosum (A) E. floccosum grown 15 d at 30°C on mMRS agar plate with no LAB
present. (B) E. floccosum grown with negative control Lb. reuteri M13. (C) E. floccosum grown with Lb. reuteri ee1p showing complete fungal inhibition.
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hydroxyisocapric acid (m/z 131.07082), hydrocinnamic acid (m/z
149.06025), phenyllactic acid (m/z 165.05517), decanoic acid
(m/z 171.1385), azelaic acid (m/z 187.09703), 4-hydroxybenzoic
acid (m/z 137.02387), p-coumaric acid (m/z 163.03952), vanillic
acid (m/z 167.03443), DL-Þ-hydroxyphenyllactic acid (m/z
181.05008) and 3-hydroxydecanoic acid (m/z 187.13342) were
identified in the Lb. reuteri ee1p strain (Fig. 4B). All identified
anti-fungal compounds were matched against their equivalent
standard peak retention times and spectra. Each identified
negative ion, [M-H]-, mass was compared with its theoretical
mass and a PPM error value was calculated. PPM errors below 3
ppm tolerance ensures that there is only one possible molecular
formula for that identified com-
pound. All identified anti-fungal compounds in the Lb. reuteri
ee1p strain had PPM errors between 0.5–2 PPM when compared
with their equivalent standard [M-H]-ions. Therefore we can
unequivalently conclude that these ten anti-fungal compounds
are present in the Lb. reuteri ee1p strain.
Dermatophyte morphology in the presence of LAB super-
natants. Lb. reuteri ee1p was used to generate a freeze-dried cell-
free supernatant (cfsP). This was added to agars to determine its
effect of fungal colony morphology for M. canis, M. gypseum and
E. floccosum. As a negative control, cfsN, a freeze-dried cell-free
supernatant of the non-antifungal strain M13 was used. As an
additional control to exclude the effect of acid, cfsC was used
which was essentially a freeze-dried uninoculated mMRS broth
which had been adjusted to pH 4.0 with lactic acid. Using
E. floccosum as an example, addition of cfsP and cfsN at a con-
centration of 0.5% did affect morphology of the fungus: fungal
colony diameter decreased from 2.5 cm (seen for cfsC and also
for the negative control plate with no additive) to 1.5 cm (with
cfsN and cfsP). At a concentration of 1%, complete inhibition of
colony growth was observed for the cfsP plate; the fungus grew
and colony diameter was 1.0 cm on the cfsN plate (negative
control). On acidified control plates to which cfsC (freeze-dried
mMRS) was added, no differences were observed when compared
with the diameter on the control plate (no additives) (Fig. 5). This
showed that cfsP contained a distinct antifungal factor or factors.
Addition of the Lb. reuteri ee1p freeze-dried cell-free supernatant
powder (cfsP) into the agar medium at concentrations greater
than 1% completely inhibited M. canis colony growth; concentra-
tions greater than 2% were necessary to inhibit M. gypseum colony
growth (data not shown).
Inhibition of fungal growth in liquid culture. Microtiter assays
were used to examine the effect of different concentrations of cfs
Figure 3. Final pH of the different lactic acid bacterial fully grown cultures in MRS broth after 48 h incubation at 37°C.
Table 3. Effect of pH on fungal growth. Fungal colony diameter (cm) after
inoculation of Microsporum canis, Microsporum gypseum and Epidermophyton
floccosum on mMRS agar adjusted to pHs ranging from 2.0 to 9.0
pH of agar 2.0 2.5 3.0 3.5 4.0 5.0 6.0 7.0 8.0 9.0
Microsporum canis 0 0 3.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
Microsporum
gypseum
0 0 3.0 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Epidermophyton
floccosum
0 0 1.8 3.0 3.0 3.0 3.0 3.0 3.0 2.5
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on M. canis, M. gypseum and E. floccosum in liquid culture. Using
M. canis as an example, when $ 5% cfsP was used, no change in
OD620 was observed over 120 h. When 1.25% or 2.5% cfsP was
added, M. canis growth was inhibited during incubation over the
same time range. Reducing the concentration of cfsP in SDB to
0.6% resulted in the loss of antifungal activity. Profiles are shown
in Figure 6. Concentrations of cfsP lower than 0.6% did not
affect the growth of M. canis (data not shown). Addition of cfsP at
Figure 4. Chromatograms of anti-fungal standards and anti-fungal compounds detected in the supernatant from Lb. reuteri ee1p following SPE clean up.54
(A) Antifungal standards: (1), (S)–(-)-2–hydroxyisocapric acid (6.80 min, m/z 131.07); (2), hydrocinnamic acid (8.48 min, m/z 149.06); (3), 3-(4-
hydroxyphenyl)–propionic acid (6.98 min, m/z 165.05); (4), phenyllactic acid (7.47 min, m/z 165.05); (5), decanoic acid (10.88 min, m/z 171.13); (6), azelaic
acid (7.57 min, m/z 187.09); (7), 4-hydroxybenzoic acid (6.18 min, m/z 137.02); (8), salicylic acid (11.97 min, m/z 137.02); (9), p-coumaric acid (7.17 min, m/z
163.03); (10), vanillic acid (6.50 min, m/z 167.03); (11), DL-Þ-hydroxyphenyllactic acid (5.00 min, m/z 181.05); (12), 3,4-dihydroxyhydrocinnamic acid
(6.23 min,m/z 181.05); (13), 3-hydroxydecanoic acid (9.32min,m/z 187.13). (B) Antifungal compounds identified in broth (1), (S)–(-)-2–hydroxyisocapric acid
(6.77 min,m/z 131.07); (2), hydrocinnamic acid (8.49 min,m/z 149.06); (4), phenyllactic acid (7.44 min,m/z 165.05); (5), decanoic acid (10.87min,m/z 171.13);
(6), azelaic acid (7.58 min,m/z 187.09); (7), 4-hydroxybenzoic acid (6.16 min,m/z 137.02); (9), p-coumaric acid (7.17 min,m/z 163.03); (10), vanillic acid (6.51
min, m/z 167.03); (11), DL-Þ-hydroxyphenyllactic acid (4.98 min, m/z 181.05); (13), 3-hydroxydecanoic acid (9.29 min, m/z 187.13).
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5% was also necessary to inhibit the other two fungi, M. gypseum
and E. floccosum (data not shown).
Discussion
Fungal infection of the skin is a common global problem.
Currently, 20–25% of the world’s population suffers from skin
mycosis, making these one of the most frequent forms of infec-
tion.2 Microsporum and Epidermophyton are two fungal
dermatophytes responsible for dermatophytosis (commonly called
tinea or ringworm) of the scalp, glabrous skin, and nails. These
fungi are frequently resistant to traditional fungicides.34 Most
antifungal agents, even those newly developed, still remain within
the two main antifungal drug families, the azoles and the
allylamines, particularly itraconazole and terbinafine. These
antifungal medications have be associated with potential hepatic
toxicity and possible drug-drug interactions.35 Therefore it is
necessary to search for more effective and less toxic novel
antifungal agents that would overcome these disadvantages.
Lactic acid bacteria are widely used for the production of
fermented foods and are also part of the intestinal microflora. A
total of 220 different isolates of LAB from a variety of environ-
ments were screened for antifungal activity by spraying fungal
spore suspensions of A. fumigatus and A. niger strains onto agar
Figure 5. Diameter (cm) of Epidermophyton floccosum colonies incubated for 15 d on Sabouraud dextrose agar plates containing freeze-dried cell-free
supernatant of Lb. reuteri ee1p at pH 4 (cfsP), freeze-dried cell-free supernatant of Lb. reuteri M13 at pH 4 (cfsN), freeze-dried mMRS at pH 4 (cfsC)
or no freeze-dried additives (control).
Figure 6. Growth of M. canis in Sabouraud dextrose broth containing 10% (X), 5% (&), 2.5% (m), 1.25% (╳), 0.6% (N) or 0% (*) of freeze-dried cell-free
supernatant of Lb. reuteri ee1p (cfsP).
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surfaces, which were then streaked with all LAB isolates. Overall,
77% of the isolates inhibited at least one fungus, 43% of all
isolates showed some degree of antifungal activity against both
target fungi, which is a very high incidence and indicates the
high sensitivity of Aspergillus to LAB. Previous studies in our
laboratory using other food fungi such as Penecillium showed
lower sensitivity in general. The reason for using Aspergillus strains
in the initial screening was that they were considered easier
and safer to work with for routine screening in our laboratory,
by comparison with many dermatophytes. The four isolates,
which showed strong antifungal activity against Aspergillus were
evaluated against M. canis, M. gypseum and E. floccosum. All
selected LAB were observed to be capable of inhibiting the three
dermatophytes. One of these strains was Lb. reuteri ee1p, was
selected for further study. Among the non-antifungal strains
identified, one namely Lb. reuteri M13 was chosen as a negative
control strain because it is very similar to Lb. reuteri ee1p in
terms of growth rate and the final pH generated in liquid culture
and thus was comparable to the antifungal strain ee1p.
The antifungal agents produced by Lb. reuteri ee1p affected
growth of both mycelia and conidia of the dermatophytes.
Addition of Lb. reuteri ee1p freeze-dried cell-free supernatant
(cfsP) into agar medium at 2% or greater had an inhibitory effect
on all fungal growth by comparison with the negative control
Lb. reuteri M13 freeze-dried cell-free supernatant (cfsN) and
freeze-dried mMRS broth (cfsC) at the same concentrations and
pH. Addition of cfsP at 5% was necessary to inhibit M. canis,
M. gypseum and E. floccosum growth in broth cultures in micro-
titer assays. When Lb. reuteri M13, a very similar strain to
Lb. reuteri ee1p in terms of growth rate and final culture pH in
liquid medium, was used as a negative control strain, much less
antifungal activity was identified. This indicated that antifungal
compounds must be specifically produced (or produced at higher
levels) by the anti-dermatophyte strain Lb. reuteri ee1p. Several
compounds with a strong antifungal activity have been isolated
from lactic acid bacterial cultures and the majority of those
identified to-date are of low molecular weight and include organic
acids,36,37 reuterin,38,39 hydrogen peroxide,29 proteinaceous com-
pounds,27,32,40 hydroxy fatty acids41 and phenolic compounds.42
Additional compounds identified in this work, which according
to the scientific literature exhibit antifungal activity43-45 are (S)–
(-)-2–Hydroxyisocapric acid (m/z 131.07082), hydrocinnamic
acid (m/z 149.06025), phenyllactic acid (m/z 165.05517),
decanoic acid (m/z 171.1385), azelaic acid (m/z 187.09703), 4-
hydroxybenzoic acid (m/z 137.02387), p-coumaric acid (m/z
163.03952), vanillic acid (m/z 167.03443), DL-Þ-Hydroxy-
phenyllactic acid (m/z 181.05008) and 3-Hydroxydecanoic acid
(m/z 187.13342). Other natural agents, which are being assessed
against dermatophytes in other laboratories, are a variety of
plant-derived agents such as the Ageratina pichinchensis var
bustamenta,46 the essential oil of Calea clematidea,16 the plant oil
of Leptospermum petersonii and Syzygium aromaticum,47 the clove
essential oil from Syzygium,48 and various organic extracts of
Nandina domestica Thunb.19 The aerial parts of Ageratina
pichinchensis were active against T. rubrum and T. mentagro-
phytes.46 The Calea clematidea oil of the leaves showed a moderate
antifungal activity against a number of Trichophyton species, with
the compound clemateol shown to be of importance in this
observation.16 The essential oils of Leptospermum petersonii and
Syzygium aromaticum showed antifungal activity against the
dermatophytes M. canis, M. gypseum, E. floccosum, T. menta-
grophytes and T. rubrum.47 Within the group of lactic acid bac-
teria examined for antifungal activity in our study, there was
considerable variation, possibly also connected with environ-
mental and genetic factors. In the context of plant-derived
antifungals, some compounds have been reported to induce side-
effects in humans. Lactic acid bacteria are widely used in food
and feed fermentation, contributing to the safety, stability, flavour
and structure of the productsit, therefore it is possible that their
antifungal agents do not induce side-effects in humans, although
this requires further research. Nevertheless, the use of lactic
acid bacteria and their products may well provide alternative or
complimentary approaches for inhibition of dermatophytes.
Previous work from our labortory reported inhibition of the
human pathgenic fungus Trichophyton tonsurans by another
Lactobacillus strain but no compounds was identified at that
point.49 This research has identified ten antifungal compounds
in strain Lb. reuteri ee1p, which are likely to play a role in the
inhibition of M. gypseum, M. canis and E. floccosum. Future
research will l ok for additional compounds as well as testing
the antifungal efficacy of purified compounds and also synergy
between compounds.
Materials and Methods
Bacterial cultures identification. Lactic acid bacteria were identi-
fied upon sequencing of the first 900 bp of the 16S rDNA.50 To
determine the closest relatives of the partial 16S rDNA sequences,
a GeneBank DNA database search was conducted. A similarity of
. 98% to 16S rDNA sequences of type strains was used as the
criterion for identification. LAB were routinely grown on MRS
agar plates (FlukaChemie AG) under microaerophilic conditions
for 48 h at 30 or 37°C. Long-term storage was done in 40%
glycerol at -80°C.
Fungal culture preparation. Initially antifungal screening was
performed by using Aspergillus fumigates J9 and Aspergillus niger
A1. Molds were cultivated on 10 ml of potato dextrose agar
(PDA) slants at 25°C for 7 d (or until sporulation occurred).
Spores were harvested by vigorously shaking slants with 20 ml
Ringer solution, providing a fungal cell and conidial suspension
of approximately 105 spores per ml. M. canis DSM10708, M.
gypseum DSM3824 and E. floccosum DSM10709 were obtained
from (DSMZ) German Collection of Microorganisms and Cell
Cultures, Germany (www.dsmz.de). The fungal pathogen was
grown on Sabouraud dextrose agar (SDA) (Sigma-Aldrich) plates
at 30°C for 15 d and then stored at 4°C until further use. Small
piece from SDA plate inoculated with sporulating colonies was
transferred into 500 ml of synthetic-nutrient-poor bouillon
(SNB).33 The suspensions were incubated at 25°C (120 rpm)
for 7–15 d to induce conidia formation. Concentrations of
1.0  105 to 3.0  105 CFU/ml were measured by plating out
serial dilutions on SDA-plates.
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Antifungal LAB screening using plate assays. Antifungal
activity of LAB against A. fumigatus J9 and A. niger A1 was
tested by nebulising 100 ml of fungal spore-mycelia suspension
(approx. 104 CFU) onto the surface of Petri-dishes containing
20 ml of MRS agar modified as follows (mMRS): pH was
adjusted to 6.0, sodium acetate and potassium dihydrogenpho-
sphate were omitted. After 30 min, bacteria were inoculated as
two parallel lines of 3 cm length; keeping a distance between
the lines of approx. 2 cm. Plates were incubated under micro-
aerophilic conditions at 30 as well as 37°C for 48 h followed
by an additional incubation for 48 h under aerobic conditions
at 25°C to promote fungal growth. The antifungal activity of
each LAB was ascertained by measuring the size of the halo
surrounding the bacterial streaks. Antifungal activity against
M. canis, M. gypseum and E. floccosum was tested by mixing 2 ml
of fungal spore-mycelia suspension into 18 ml of MRS agar
modified as follows (mMRS): pH adjusted to 6.0, sodium acetate
as well as potassium dihydrogenphosphate were omitted. After
30 min, lactic acid bacteria were inoculated as two parallel lines
of 3 cm length; keeping a distance between the lines of approx.
2 cm. Plates were incubated under microaerophilic conditions
at 30 or 37°C for 48 h followed by an additional incubation for
15 d under aerobic conditions at 30°C to promote fungal growth.
The antifungal activity of each LAB was ascertained by measuring
the size of the halo surrounding the bacterial streaks. The overall
growth of the fungi was compared with that in control plates (i.e.,
with no LAB present).
Analysis for reuterin production using colorimetric assay.
Reuterin [3-hydroxypropionaldehyde (3-HPA)] was tested using
the chemical method of Cohen and Altshuller,51 and Cadieux
et al.39 Briefly, cells were harvested from liquid cultures by centri-
fugation and washed twice with 50 mM potassium phosphate
buffer (pH 7.5). Approximately 100 mg cells (wet weight) were
resuspended in 14 mL 250 mM glycerol, and the cells in glycerol
were incubated at 37°C for 2 h. The supernatant was passed
through a 0.45-mm-pore-size syringe filter and stored at 4°C. The
assay for 3-HPA content was based on Cohen and Altshuller49
colorimetric method developed for acrolein. 3-HPA was first
dehydrated to acrolein, which in turn reacts with 4-hexylresorcinol,
in the presence of HgCl2 as catalyst, to form a colored complex
that absorbs light at 605 nm. Briefly, 0.5 ml saturated trichlo-
roacetic acid (TCA), 0.012 ml of a 4-hexylresorcinol solution
(50% w/v inethanol) and 0.02 ml of an HgCl2 solution (3%
w/v in ethanol) were mixed with 0.5 ml of sample. The mixture
was incubated at 60°C for15 min, allowed to cool down at 20°C
for an additional 15 min and the absorbance immediately
recorded at 605 nm. Sample was diluted to assure absorbance
readings below 0.85. Since 3-HPA is not commercially available,
acrolein, a derivative of 3-HPA was used at 0.05mM, 0.5 mM
and 50 mM as positive controls (1 mol of 3-HPA dehydrates to
1 mol of acrolein) as previously described by Bauer et al.52
Production of cell-free supernatant (cfs) powders of lactic
acid bacteria. Freeze-dried supernatant powders of the most
inhibiting (positive) strain, cfsP, and of a non-inhibiting strain
belonging to the same species (cfsN) were produced to serve as
base material for the experiments describing the nature of the
antifungal compounds. Briefly, overnight cultures of bacteria
were inoculated in 500 ml of mMRS broth to reach an initial
concentration of 104 CFU/ml. The bacteria were grown for 5 d
at 37°C (temperature at which the antifungal strain showed its
highest activity). Cells were separated from the supernatant by
centrifuging twice at 3,000 g for 15 min. The cell-free super-
natant was freeze-dried and the powder stored at 4°C. Freeze-
dried mMRS broth (cfsC) powder, which was used as a control
for some experiments, was obtained using same procedure.
Typically, 500 ml of supernatant gave rise to 25 g of lyophilized
powder. Powders were routinely reconstituted in sterile distilled
water.
pH tolerance testing of M. canis, M. gypseum and
E. floccosum. The pH tolerance of M. canis, M. gypseum and
E. floccosum were evaluated by adjusting the pH of mMRS to
2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0 using either
HCl or NaOH. 10 mL of spore-mycelia suspension were ino-
culated as a spot in the center of the mMRS plates after which
they were incubated for 15 d at 30°C under aerobic conditions.
pH susceptibility was monitored by measuring the diameter of
fungal colonies at the different pHs.
Identification of antifungal compounds from Lb. reuteri
ee1p using LC-FTMS. Anti-fungal standard compounds: (1) (S)-
(-)-2-hydroxyis capric acid; (2) hydrocinnamic acid; (3) 3-(4-
hydroxyphenyl)-propionic acid; (5) decanoic acid; (6) azelaic acid;
(7) 4-hydroxybenzoic acid; (8) salicylic acid; (9) p-coumaric acid;
(10) vanillic acid; (11) DL-Þ-hydroxyphenyllactic acid; (12) 3,4-
dihydroxyhydrocinnamic acid; (13) 3-hydroxydecanoic acid) and
the mobile phase additive acetic acid were purchased from Sigma
Aldrich. (4) Phenyllactic acid was obtained by Bachem (Weil am
Rhein). LC-MS grade solvents were sourced from Thermo Fisher
Scientific. Solid phase extraction (SPE) cartridges (Isolate C18-
EC) were purchased from Biotage AB.
Separation of the 13 compounds was obtained on an Accela
LC system (Thermo Fisher Scientific) using a Gemini C18 (150 
2 mm, 5 mm; Phenomenex) column equipped with a Security
Guard cartridge (C18, 4  2 mm; Phenomenex). The column
was maintained at a temperature of 30oC and a flow rate of
300 ml/min. A stepped gradient elution was used (A-water with
0.1% acetic acid; B-acetonitrile with 0.1% acetic acid). Initial
conditions were 10% B held for 3 min increasing to 95% B over
10 min, this was held for 3 min, before returning to the initial
starting conditions to equilibrate.53 Sample preparation involved
applying the crude Lb. reuteri ee1p extract, following centrifu-
gation, to an Isolate C18-EC SPE cartridge as outlined in the
method by Strom et al.54
The LTQ Orbitrap XL hybrid mass spectrometer (Thermo
Fisher Scientific) was connected to the Accela LC system. It was
operated in negative ion mode with an electrospray interface
(ESI). A universal ion source tune method was developed opti-
mising the capillary temperature at 300°C, capillary voltage at
-50 V, tube lens at -110 V, sheath gas at 45 arb and the auxiliary
gas at 15 arb. The instrument was calibrated as per the manu-
facture’s instructions and applied at a resolution of 30,000
FWHM giving sufficient data points (n = 15) under each
chromatographic peak.53
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Fungal morphology in the presence of LAB supernatant. A
50% (w/w) cfsP, cfsN and cfsC working-solution were prepared
by dissolving the powder in distilled water, adjusted pH to 4
using commercial D/L-lactic acid (Sigma-Aldrich) and variable
amounts of 4 M NaOH, and then filter sterilized using a
0.45 mm MINISART1-plus filter (Sartorius). SDA plates were
prepared containing 0 (control), 0.5, 1, 2% (m/v) cfsP. For each
concentration, negative control plates were prepared containing
same amount of cfsN, acidified control plates were prepared
containing same amount of cfsC. After cooling, 10 uL of spore-
mycelia suspension were inoculated as a spot in the center of
the SDA-plates. The plates were incubated for 15 d at 30°C
under aerobic conditions. The fungal growth was monitored by
measuring the growth area of fungal colonies.
Inhibition of fungal growth in liquid culture. The effect of
different concentration of cfsP on the growth of M. canis,
M. gypseum and E. floccosum were examined by using a microplate
assay. The spore suspension was adjusted to 1.0  105 ml21.
Aliquots of 50 ml were centrifuged at 3000 g for 10 min and
the supernatant was discarded. The conidia pellets were
resuspended in 5 ml Sabouraud dextrose broth (SDB), and
then 100ul of conidia solution were adding to the wells of a
sterile 96-well microplate (Sarstedt AG and Co.). 100 ml of cfsP
dilutions were adding to the wells, and the final concentrations
of cfsP were 0, 0.075, 0.15, 0.3, 0.6, 1.25, 2.5, 5.0, 10 or 20.0
(%). The microplate was sealed with optically clear seal for
QPCR (Thermo Scientific). The microplates were incubated for
120 h at 30°C inside a Multiskan FC microplate-reader
(Thermo Scientific). The optical density at 620 nm (OD620)
was automatically recorded for each well every 3 h. The changes
in OD620 over time were used to generate dermatophytes’
growth curves at each cfsP concentration. The experiment was
performed in duplicate.
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